key: cord-0725911-kcy5r01l authors: Kovacech, Branislav; Fialova, Lubica; Filipcik, Peter; Skrabana, Rostislav; Zilkova, Monika; Paulenka-Ivanovova, Natalia; Kovac, Andrej; Palova, Denisa; Paulíkova Rolkova, Gabriela; Tomkova, Katarina; Csokova, Natalia Turic; Markova, Karina; Skrabanova, Michaela; Sinska, Kristina; Basheer, Neha; Majerova, Petra; Hanes, Jozef; Parrak, Vojtech; Prcina, Michal; Cehlar, Ondrej; Cente, Martin; Piestansky, Juraj; Fresser, Michal; Novak, Michal; Slavikova, Monika; Borsova, Kristina; Cabanova, Viktoria; Brejova, Bronislava; Vinař, Tomas; Nosek, Jozef; Klempa, Boris; Zilka, Norbert; Kontsekova, Eva title: Second-Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern date: 2021-06-09 journal: bioRxiv DOI: 10.1101/2021.06.09.447527 sha: fb3eb032ac931155c181b7a4133536e85270cb59 doc_id: 725911 cord_uid: kcy5r01l Recently emerged SARS-CoV-2 variants show resistance to some antibodies that were authorized for emergency use. We employed hybridoma technology combined with authentic virus assays to develop second-generation antibodies, which were specifically selected for their ability to neutralize new variants of SARS-CoV-2. AX290 and AX677, two monoclonal antibodies with non-overlapping epitopes, exhibit subnanomolar or nanomolar affinities to the receptor binding domain of the viral Spike protein carrying amino acid substitutions N501Y, N439K, E484K, K417N, and a combination N501Y/E484K/K417N found in the circulating virus variants. The antibodies showed excellent neutralization of an authentic SARS-CoV-2 virus representing strains circulating in Europe in spring 2020 and also the variants of concern B.1.1.7 and B.1.351. Finally, the combination of the two antibodies prevented the appearance of escape mutations of the authentic SARS-CoV-2 virus. The neutralizing properties were fully reproduced in chimeric mouse-human versions, which may represent a promising tool for COVID-19 therapy. Neutralizing antibodies (NAbs) against SARS-CoV-2 are being evaluated for prophylaxis and as therapeutic agents for COVID-19 patients 1 . Human antibodies isolated from COVID-19 convalescent patients often target the receptor-binding domain (RBD) of the Spike (S) protein of SARS-CoV-2, and recognize distinct, sometimes non-overlapping epitopes [2] [3] [4] [5] [6] [7] [8] . Only a small subset of these antibodies can block viral entry, usually by interfering with the binding of the viral S protein to the cellular receptor ACE2 2, 4, 5 . Clinical trials suggest that antibody treatments can prevent deaths and hospitalizations among people with mild or moderate COVID-19. Some of therapeutic antibodies against COVID-19 were already authorized for emergency use 9 , however they were not initially selected for the neutralization activity on emerging variants of COVID-19. The majority of neutralizing antibodies against SARS-CoV-2 in the clinical development was derived from convalescent patients who recovered from COVID-19 [10] [11] [12] [13] . Antibodies derived from human B cells do not require an extensive humanization process and can be fast-forwarded to manufacture 14 . However, several studies demonstrated that neutralizing monoclonal antibodies obtained from individuals during the early convalescence period may exhibit low levels of maturation associated with viral suppression of germinal center development 15, 16 . Neargermline human antibodies could cross react with antigens in mammalian tissues 17 . Optimal immunization procedure and exploration of mouse immunoglobulin repertoire may overcome these limitations and survey an orthogonal conformation space of antibody specificities 18 . The emergence of new SARS-CoV-2 variants of concern (VOCs) B.1.1.7 (South East of England) 19, 20 , B.1.351 (South Africa) 21 , and P. 1 (Brazil) 22, 23 that harbor mutations in the viral S protein raised alarm whether current vaccines and therapeutic antibodies were sufficiently effective. Indeed, several independent studies have shown that mutant variants are partially or completely resistant against therapeutic antibodies that were authorized for emergency use [24] [25] [26] [27] [28] . Here we present two mouse-human chimeric monoclonal antibodies against the S protein RBD with non-overlapping epitopes and excellent neutralization potency not only against a live authentic SARS-CoV-2 virus isolate that circulated in Europe in spring 2020, but also variants of concern B.1.1.7 and B.1.351 currently spreading in the population. The combination of the two antibodies prevents generation of escape mutations of the live authentic SARS-CoV-2 virus, making the mixture a promising candidate for a therapeutic application. To isolate fully matured antibodies with high neutralizing potency against live SARS-CoV-2 virus, we immunized mice either with the recombinant Spike protein or its RBD. Screening of the best antibody-expressing mouse hybridoma clones generated from mice immunized with the viral Spike protein revealed that all except one (98%) target RBD of the SARS-CoV-2 S protein ( Figure 1A ). Nineteen out of 23 hybridoma clones from RBD-immunized mice produced antibodies recognizing the S protein ( Figure 1B The neutralizing antibodies bind RBD with nanomolar or sub-nanomolar affinities ( Figure 1H ). Kinetic SPR experiments revealed that antibodies exhibited a large distribution of dissociation kinetic rates, spanning two orders of magnitude (1.3x10 -4 -1.8x10 -2 s -1 ; Figure 1H , I). The association kinetics also varied, but to a lesser extent (4.6x10 5 -1.7x10 6 M -1 s -1 ). Four antibodies with the highest (picomolar) affinities, AX12, AX96, AX290 and AX677, had very slow dissociation rates below 10 -3 s -1 . Six antibodies showed nearly identical affinities of 2 to 3 nM (AX68, AX97, AX99, AX266, AX322 and AX352), but with contrasting kinetic behaviour. In general, the antibodies exhibit RBD binding affinities similar to or better than antibodies isolated from patient sera 12, 24, 25 . Mutual competition of the selected antibodies for binding to RBD revealed three nonoverlapping antibody epitopes ( Figure 2A , Epitopes I, II, III). Epitope I was recognized by the group of six antibodies, which appeared among the best neutralizers of the authentic live SARS-CoV-2 virus. Within this group, the virus neutralization activities highly correlated with their affinities to RBD (R 2 >0.9). The Epitope II group comprised six antibodies, where AX677 and AX175 did not compete with each other. One antibody (AX12) recognised a non-overlapping independent region (Epitope III). AX290 and AX677 showed the highest binding affinities to RBD of all members of the Epitope I and II groups, respectively, and showed the highest neutralizing activities against the live authentic virus. We applied hydrogen-deuterium exchange coupled to mass spectrometry (HDX) to identify their binding sites on RBD. Deuterium uptake was monitored on 288 unique peptides, covering 89% of the RBD sequence. The peptides protected by AX677 antibody included amino Figure 2C , D). The epitope of AX290 is located in the region of RBD that comprises some of the contacts to ACE2, is often targeted by neutralizing Abs 2 , and overlaps with epitopes of REGN10933 and LY-CoV555 12,30 . The epitope of AX677 is located outside of the ACE2-binding interface, which explains why it does not inhibit ACE2-RBD interaction. Its mode of neutralization might be allosteric or via interference with attachment to other cell surface molecules. In order to test the ability of the selected mAbs to bind RBD with the mutations that appear in the current SARS-CoV-2 VOCs, B.1.1.7 (N501Y) and B.1.351 (K417N/E484K/N501Y), we screened the mutated RBDs by ELISA ( Figure 3A, B) . None of the mutations completely prevented recognition by the antibodies. Individual mutations N501Y, K417N and E484K, and N439K mutation (widespread in Europe), had only a marginal impact on the antibody binding. The combination K417N/E484K/N501Y exhibited either no or only minor influence on the binding of the antibodies of the Epitope I group. The mutations showed practically no influence on antibodies AX99, AX677 and AX97 of the Epitope II group. E484K, however, reduced binding of AX322, AX175 and partially also AX67 to RBD. E484K and N501Y made the highest impact on the binding of these mAbs to RBD containing the triple mutation SARS-CoV-2 virus has accumulated mutations resulting in compromised activities of some vaccines and therapeutic antibodies 30, 31 . We, therefore, examined the ability of the authentic virus to escape from the selection pressure of AX290 and AX677, the best neutralizing mAbs with non-overlapping epitopes, alone and in combination ( Figure 5A , B). It has been shown that an S-typed pseudoviruses might not fully recapitulate the complex behaviour of the authentic SARS-CoV-2 as measured by neutralizing activities of tested antibodies 32 . We have also observed that our highly neutralizing antibodies behave differently on S-pseudotyped mouse leukemia virus (MLV), AX677 did not neutralize it while AX290 did ( Figure 1C ). Therefore, we have used live authentic virus isolate Slovakia/SK-BMC5/2020, that represents strains circulating in Europe in spring 2020, for the escape test. The virus particles, preincubated with serially diluted antibodies (individual or their 1:1 mixture), were used to infect Vero E6 cells. When the cytopathic effect of the escaping viruses became evident, the cell culture media with the escaping viruses (wells with approx. 30% cells affected) were collected, again preincubated with the respective serially diluted antibodies and added to fresh Vero E6 cells for another round of mutant virus amplification ( Figure 5A ). Sequence analysis of the viruses that escaped from the neutralization by the individual antibodies revealed only one mutation in the Spike protein per antibody: a S477R substitution for AX290, and a T345N substitution for AX677 ( Figure 5B ). The S477R substitution that allowed escape of the virus from AX290 is located in the region of RBD that was identified by HDX as the contact site of the antibody ( Figure 5C ). It was found in 0.0705% of the sequenced SARS-CoV-2 isolates so far (https://www.gisaid.org/hcov19mutation-dashboard/, database version as of May 23, 2021, 1621641 sequences analysed). The alternative substitution S477N that is more widespread in circulating viruses (3.31%) was not found in the sequenced viral genomes. The mutation T345N present in the escape virus mutant against AX677 is positioned close to peptides protected by the antibody, but not directly within their sequence. It is a very rare mutation, only one T-N substitution at the position 345 of Spike has been found in circulating viruses, and only 32 substitutions of T345 were detected in the GISAID database until now. It is possible that this region of Spike RBD is less targeted by human immune repertoire resulting in a low selection pressure, or mutations there compromise the viral fitness. The T345N escape mutation has also been identified previously using an S-typed VSV pseudovirus for antibody 2H04 33 , which also did not compete with ACE2 for binding to the S protein. Importantly, no escape mutation in the Spike protein was detected with the antibody mixture. The cytopathic effect appeared simply due to the dilution of the antibody concentration below the threshold required to neutralize the virus (625-fold higher dilution than any single mAb in the second passage). This shows that the combined therapy with both AX290 and AX677 would provide a potent barrier impeding viral replication and would protect against the mutational escape. In order to prepare AX290 and AX677 for clinical testing, their variable regions were fused to human kappa and IgG1 constant regions. The chimeric mAbs AX290ch and AX677ch exhibited similar binding and functional properties as parental mouse versions. Both chimeric antibodies bound various mutant forms of RBD in ELISA with similar activities ( Figure 6A ). The chimeric antibodies recognised all tested mutants with nanomolar or sub-nanomolar affinities, which guarantees their unmodified neutralizing capacity ( Figure 6B ). Numerically, AX290ch maintained its picomolar affinity to all mutants except those containing K417N mutation alone or in combination N501Y/E484K/K417N (3-fold and 2-fold decrease in the affinity, respectively). AX677ch binds N501Y mutation, with 1.4-fold higher affinity than wild type RBD, reaching picomolar values ( Figure 6B ). Furthermore, this positive effect of the N501Y mutation is propagated into the triple mutant combining mutations N501, E484K, and K417N, which AX677ch binds with higher affinity than either of the two single mutants E484K and K417N, and even wild type RBD (1.4-, 1.7-and 1.2-fold, respectively). The chimeras efficiently neutralized live authentic SARS-CoV-2 virus, Slovakia/SK-BMC5/2020 isolate (B.1 lineage), and variants of concern B.1.1.7 and B.1.351, in PRNT ( Figure 6C ). The tests confirmed that the neutralizing activity was fully preserved in the chimeric versions of the antibodies. Monoclonal antibodies targeting the viral protein S have enormous potential to prevent SARS-CoV-2 infection and treat patients with mild to moderate COVID-19 34 [20] [21] [22] [23] , raised concern about the efficacy of vaccines and therapeutic antibodies 26, 30, 31 . It was indeed shown that SARS-CoV-2 variants B.1.351 and P.1 were partially (REGN10933) or completely (LY-CoV555) resistant against antibodies used for COVID-19 treatment 30 . This is in concordance with a study showing that the interaction between the mutant RBD containing three mutations N417/K484/Y501 and LY-CoV555/Bamlanivimab was completely abolished 31 . To avoid this therapeutic limitation, we screened and selected the antibodies showing neutralization activity against several variants of SARS-CoV-2. We took advantage of the mouse immunoglobulin repertoire 18 through the hybridoma technology to isolate monoclonal antibodies neutralizing live authentic SARS-CoV-2 virus. The in vitro and live virus screening assays allowed us to identify two neutralizing antibodies, AX290 and AX677, each of them neutralizing live authentic SARS-CoV-2 virus circulating in Europe in the spring of 2020 and two fast-spreading authentic variants of concern B.1.1.7 and B.1.351. It is important to emphasize that the antibodies were resistant to the E484K mutation, which has been recently shown to endow the S-typed VSV pseudovirus with resistance to several human convalescent sera 33 . The authors have suggested that the repertoire of antigenic sites on RBD is limited in some individuals and that this amino acid is a part of a dominant neutralizing epitope. The use of a live authentic SARS-CoV-2 virus to identify the escape mutations, as opposed to other studies that employed an S-typed pseudovirus 10, 33, [35] [36] [37] [38] , allowed to eliminate a potential bias from an inadequate infection and replication machinery of a model virus. It has been noted that only some of the spike escape mutations identified in SARS-CoV-2 S-typed infectious vesicular stomatitis virus were found so far in the context of authentic SARS-CoV-2 virus isolates, it is possible that those not identified might compromise the fitness of the genuine virus 33 . Our authentic virus approach identified antibody-specific escape mutations in RBD of the Spike protein, S477R and T345N, that directly affect the recognition by the antibodies. The combination of the two antibodies exhibits a strong synergistic neutralizing effect against the authentic live SARS-CoV-2 virus observable at >600-fold lower concentration than each antibody alone. More importantly, the antibody combination also prevented emergence of escape mutations of the authentic SARS-CoV-2 virus. The potential for an effective COVID-19 treatment and protection against antibody resistance is strengthened by the fact that they bind non-overlapping epitopes on functionally different portions of the S protein RBD and apparently different mechanisms of how the two antibodies neutralize the virus. In addition, the chimeric antibodies AX290ch and AX677ch showed similar binding potencies against various mutations located in RBD and effectively neutralized SARS-CoV-2 variants of concern. We recognize that the resistance of the antibody cocktail against the virus escape mutations was not confirmed in PRNT. The mechanism of virus neutralization by AX677 has not yet been understood. The study was funded by AXON Neuroscience SE. Human embryonic kidney HEK293T/17-hACE2 cells with stable expression of human angiotensin-converting enzyme ACE2 (AXON Neuroscience SE) were prepared by stable transfection of pDUO2-hACE2-TMPRSS2a (InvivoGen) with transfection reagent The prefusion-stabilized SARS-CoV-2 S protein ectodomain (residues 1−1208 from GenBank: Proteins were produced in human cell line Expi293. Plasmids that drive protein expression from the CMV promoter were either transfected with polyethyleneimine (PEI) or by electroporation into Expi293 cells that were in exponential growth phase. For PEI transfections, 3.75ml PEI and 1.25mg DNA was added to a suspension of 10 9 cells in a total volume of 50 ml, shaken at 37°C for 3 hrs and diluted into working concentrations. For electroporation, 100 µg/ml DNA was electroporated in a suspension of 2.10 8 cells/ml in electroporation buffer using MaxCyte STX (MaxCyte, MD, USA), the cells were let to rest for 30 min and then diluted into the final concentration of 3.10 6 cells/ml. The cultures were incubated with shaking at 37°C for 24 hrs, transferred to 32°C and further cultured until cell viability decreased to <50% (approx. 4-6 days), at which point the medium was harvested by centrifugation at 300xg for 12 min and stored at -20°C until purification. The proteins were purified from cell media using Åkta FPLC (GE Healthcare) as follows. The Six-week-old Balb/cN mice were primed subcutaneously either with 30 The growing hybridomas were screened for the production of monoclonal antibodies specific to the S protein and RBD by an enzyme-linked immunosorbent assay (ELISA). Microtiter plates were coated overnight with one of the proteins (2 μg/ml, 50 μl/well) at 37°C in PBS. After Readouts with an absorbance value of at least twice the value of the negative controls (PBS) were considered positive. ELISA positive hybridoma cultures were further subcloned in soft agar according to the procedure described previously 39 . After purified hybridoma clones were obtained, the antibodies isotypes were determined by ELISA using a mouse Ig isotyping kit (ISO-2, SIGMA). Kinetic characteristics and affinities of mouse and chimeric antibodies to RBD was measured by SPR. A BIACORE3000 instrument with a CM5 sensor chip (Cytiva, USA) was used for the SPR assays. Amine-coupling reagents (EDC, NHS, ethanolamine pH 8.5), were obtained from Cytiva. 40 . On-and off-rates were fitted locally, maximal response was fitted globally and the bulk response was set to zero. The equilibrium dissociation constants KD of antibody-RBD complexes were calculated from the averaged association and dissociation rate constants. The final error of affinities was propagated from errors of the experimental rate constants used for KD calculation. With the aim to select the antibodies blocking the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor, ELISA-based inhibition test was used. (1 -(absorbance of antibody/absorbance of positive control) × 100. HEK 293T/17 cells stably expressing human ACE2 protein (HEK 293T/17-hACE2) were seeded at 60-70% plating density in 48-well plates and cultivated O/N at 37°C, 5% CO2 in a humidified incubator in DMEM supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 100 units/mL penicillin/streptomycin (all from Life Technologies Invitrogen, Carlsbad, CA, USA) and 100 µg/ml hygromycin (Thermo Fisher Scientific). Recombinant Spike protein was labelled with Alexa Fluor TM 546 (Thermo Fisher Scientific) according to the manufacturer's recommendations. Labelled S protein (40 ng/ml) was preincubated with tested hybridoma culture supernatants producing mAbs (diluted 1:50 in DMEM) for 30min at 37°C. Then the preincubation mixtures were added to HEK 293T/17-hACE2 cells and incubated for 2 hrs at 37°C, 5% CO2 in a humidified incubator. Subsequently, cells were gently re-suspended in 500 µl PBS, transferred into flow cytometry tubes and immediately evaluated for S protein internalization by flow cytometry. Cells were gated using forward and side scatter to exclude cellular debris. The FSC-H/FSC-A gating approach was used to eliminate doublets. Measurements were recorded as mean fluorescent intensity of Alexa Fluor 546. Approx. 10 000 cells were quantified for each microtiter plate well. Fluorescence data were normalized to cells treated with the labelled S protein pre-incubated with a hybridoma culture supernatant from a clone producing an irrelevant antibody. IC50 values for particular experiments were calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software Inc.). For testing the neutralization ability of monoclonal antibodies, the procedure adapted according For the first round of the escape mutant selection, SARS-CoV-2 virus at a high multiplicity of infection (MOI) of 0.5 was added to each dilution of mAbs (5-fold serial dilution starting at 50 µg/mL) and incubated at 37°C for 1hr. The mixture was then transferred to 12-well plates containing sub-confluent Vero E6 cell monolayer. Plates were incubated 3-4 days at 37°C and 5% CO2 and examined for the presence of a cytopathic effect (CPE). Supernatants from the first wells in the mAb dilution series with evident CPE (approx. 30% cells affected) were collected. For the second passage, these supernatants were diluted 1:5 in DMEM and pre-incubated for 1hr at 37°C in the presence of serially 5-fold diluted mAbs starting at 100 µg/mL. After incubation at 37°C for 1hr, the mixture was transferred to 12-well plates with Vero E6 cells and further incubated 3-4 days at 37°C. Total RNA, including the viral RNA, was extracted from the cells in the first wells of the mAb dilution series that show CPE and used for the sequencing. The sequencing libraries were constructed essentially as described in the Eco PCR tiling of SARS-CoV-2 virus with native barcoding protocol (Oxford Nanopore Technologies), except the amplicons spanning the SARS-CoV-2 genome sequence were generated using the ~2. Raw nanopore data was base called and demultiplexed using Guppy v.4.4.1. Barcodes at both ends were required in demultiplexing. Variants were called using the ARTIC pipeline (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html), which internally filters reads based on quality and length, aligns them to the reference (Wuhan-Hu-1 isolate, NC_045512) using minimap2 (https://github.com/lh3/minimap2), trims primers, and calls variants using Nanopolish (https://github.com/jts/nanopolish). All variants reported in Table S1 were determined based on read coverage of at least 380. All new nonsynonymous mutations were supported by at least 90% of the analyzed reads overlapping a particular site. Note that due to higher error rates of nanopore sequencing, even fixed variants typically do not achieve 100% support. HEK293T/17-hACE2 cells were plated on cover glass pre-coated with rat-tail collagen, type I (Sigma-Aldrich, St. Louis, Missouri, United States) and cultivated for 24 h in DMEM with 10% FCS. Cells were fixed with 4% paraformaldehyde and labelled with anti-human ACE2 antibody at 10 µg/ml (cat. # 600-401-X59; Rockland Immunochemicals), followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green; cat. # A-11008; Invitrogen). The samples were mounted in Fluoroshield TM medium with DAPI (Sigma-Aldrich). Images were captured by LSM 710 confocal microscope (Zeiss, Jena, Germany). RBD and AX290 or AX677 were dissolved in non-deuterated PBS buffer (Phosphate Buffered COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19 SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells Human neutralizing antibodies elicited by SARS-CoV-2 infection Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model Potently neutralizing and protective human antibodies against SARS-CoV-2 Antibodies to watch in 2021 Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 Neutralizing antibodies targeting SARS-CoV-2 spike protein Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients A Therapeutic Nonself-reactive SARS-CoV-2 Antibody Protects from Lung On being the right size: antibody repertoire formation in the mouse and human Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early data-driven analysis S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil Detection of B.1.351 SARS-CoV-2 Variant Strain -Zambia LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape One-step method for establishing 8-azaguanine-resistant hybridomas suitable for the preparation of triomas Improving biosensor analysis SARS-CoV-2 Genome Sequencing Using Long Pooled Amplicons on Illumina Platforms SARS-CoV-2 genomes recovered by long amplicon tiling multiplex approach using nanopore sequencing and applicable to other sequencing platforms MSTools-Web based application for visualization and presentation of HXMS data Blocking of interaction between RBD and ACE2 in a competition assay based on ELISA (RBD-ACE2), inhibition of the S protein internalization by cells expressing ACE2 (S-ACE2), inhibition of cell infection by MLV pseudotyped with SARS-CoV-2 spike protein (Pseudovirus) and plaque reduction neutralization test performed with an authentic SARS-CoV-2 virus isolate Experiments were done with hybridoma culture supernatants adjusted with fresh cell culture medium to the same mAb concentration and then diluted for the assays as follows cell assay 1:50 in DMEM; pseudoviral assay 1:25 in DMEM; live virus PRNT 1:50 in EMEM. Positive control: serum of a mouse immunized with the S protein All experiments are an average of at least two measurements, pseudoviral tests were all done in tetraplicates D) The purified monoclonal antibodies were tested for the inhibition of ACE2-mediated S protein internalization by HEK293/17-hACE2 cells, blocking the RBD-ACE2 interaction in competitive ELISA (E) and plaque reduction neutralization test (F) performed with strain The curves are calculated from 2 replicates using Prism 6 for Windows H, I) Kinetic characteristics of the interactions of RBD with selected neutralizing antibodies On-rate (ka), off-rate (kd) constants and equilibrium dissociation constant (KD) of individual antibody-RBD complexes (±SD)